Long‐term benefits of darifenacin treatment for patient quality of life: Results from a 2‐year extension study
暂无分享,去创建一个
C. Kelleher | F. Haab | P. Dwyer | R. Ariely | K. Lheritier | U. Ebinger | Jay M. Young
[1] C. Kelleher,et al. Clinical relevance of health‐related quality of life outcomes with darifenacin , 2008, BJU international.
[2] T. Wilt,et al. Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women , 2008, Annals of Internal Medicine.
[3] M. Elhilali,et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study , 2007, Current medical research and opinion.
[4] S. Bolge,et al. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder , 2007, Current medical research and opinion.
[5] N. Zinner. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder , 2007, Expert opinion on pharmacotherapy.
[6] C. Kelleher,et al. Redefining response in overactive bladder syndrome , 2007, BJU international.
[7] K. Coyne,et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.
[8] W. Steers,et al. Long‐term treatment with darifenacin for overactive bladder: results of a 2‐year, open‐label extension study , 2006, BJU international.
[9] I. Hussain,et al. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. , 2006, Urology.
[10] Z. Gabriel,et al. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. , 2006, Urology.
[11] P. Abrams,et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder , 2005, BJU international.
[12] C. Kelleher,et al. 228The emotional burden of overactive bladder (OAB) symptoms on sufferers , 2005 .
[13] W. Steers,et al. An investigation of dose titration with darifenacin, an M3‐selective receptor antagonist , 2005, BJU international.
[14] C. Kelleher,et al. How much is enough and who says so? , 2004, BJOG : an international journal of obstetrics and gynaecology.
[15] F. Haab,et al. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. , 2004, European urology.
[16] K. Andersson. Antimuscarinics for treatment of overactive bladder , 2004, The Lancet Neurology.
[17] C. Kelleher,et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder , 2003, Quality of Life Research.
[18] W. Stewart,et al. Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.
[19] C. Kelleher. Economic and Social Impact of OAB , 2002 .
[20] Magnus Fall,et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.
[21] R. Lipton,et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. , 2001, Urology.
[22] C. Kelleher,et al. Overactive bladder significantly affects quality of life. , 2000, The American journal of managed care.
[23] L. Cardozo,et al. A new questionnaire to assess the quality of life of urinary incontinent women , 1997, British journal of obstetrics and gynaecology.